fintols

Elevance Health vs Regeneron (ELV vs REGN)

Elevance Health (ELV) vs Regeneron (REGN) in plain English: P/E, growth, margins, debt and dividend side by side, key differences and which fits each investor profile.

Elevance Health (ELV) and Regeneron (REGN) compete in healthcare and pharma. Here are Elevance Health and Regeneron side by side with their real figures as of November 4, 2026: what sets them apart, which fits each kind of investor and the most common questions, without telling you whether to buy Elevance Health or Regeneron.

Elevance Health vs Regeneron: the figures

FigureElevance HealthRegeneron
Share price$434.18 (November 4, 2026)$930.67 (November 4, 2026)
Market cap$94.2 billion$96.3 billion
P/E (TTM)18.4x20.6x
Forward P/E14.3x13.2x
Revenue growth (quarter)+1.4%+36.3%
Net margin (TTM)2.5%28.5%
Net debt / EBITDANet cashNet cash
Dividend yield1.66%0.39%
Beta0.630.10

Elevance Health and Regeneron figures from Yahoo Finance, the same source the Fintols analysis uses, retrieved on November 4, 2026; N/A means that Elevance Health or Regeneron figure is not available, and we never estimate it.

3 key differences between Elevance Health and Regeneron

  1. Growth: Regeneron grew sales +36.3% year on year in its latest quarter, against +1.4% for Elevance Health.
  2. Profitability: for every 100 of sales, Regeneron keeps 28.5 as net profit and Elevance Health keeps 2.5.
  3. Volatility: Elevance Health stock moves more (beta 0.63) than Regeneron (beta 0.10); the higher the beta, the more it amplifies market swings.

Elevance Health or Regeneron: which fits your profile

Neither Elevance Health nor Regeneron wins on everything, and owning both is also an option: spreading money across several companies or an index fund reduces what rides on each one.

How Elevance Health and Regeneron make money

Elevance Health (ELV)

Elevance Health, formerly Anthem, sells health insurance under names like Anthem Blue Cross and Wellpoint to employers, individuals and government programs such as Medicaid and Medicare. Its segments are Health Benefits, the largest, CarelonRx, which manages pharmacy benefits, and Carelon Services, which provides care delivery and health services. Full Elevance Health analysis.

Regeneron (REGN)

Regeneron is a biotech company built on antibody drugs. It earns money from U.S. sales of Eylea for retinal eye disease and from its partnership with Sanofi on Dupixent, used for eczema and asthma, which the two companies share profits on. It also sells the cancer immunotherapy Libtayo. Full Regeneron analysis.

Frequently asked questions: Elevance Health vs Regeneron

Is Elevance Health or Regeneron the better stock?

Choosing between Elevance Health and Regeneron depends on what you are looking for. Regeneron is growing faster right now, and Elevance Health trades on the lower P/E. Fintols does not tell you whether to buy Elevance Health or Regeneron: it shows you the differences so you can decide.

Which pays a higher dividend, Elevance Health or Regeneron?

As of November 4, 2026, Elevance Health yields 1.66% and Regeneron yields 0.39%. Also check how much of their profit Elevance Health and Regeneron pay out: if it is more than they earn, it cannot last.

Which is more expensive, Elevance Health or Regeneron?

On P/E, Regeneron (20.6x) is more expensive than Elevance Health (18.4x) as of November 4, 2026. A higher P/E can be justified if earnings grow faster, so compare it with each company's growth in the table.

Can I own both Elevance Health and Regeneron?

Yes. Many people spread their money across several companies, such as Elevance Health and Regeneron, or use index funds so they do not depend on just one. If you are starting out, decide how much you want to invest and for how long before buying Elevance Health or Regeneron.

More comparisons with Elevance Health or Regeneron

More companies like Elevance Health and Regeneron: healthcare and pharma stocks. Educational content about Elevance Health and Regeneron, not investment advice.